publication venue for DEVELOPMENT OF NOVEL, NONTOXIC RIFAMYCINS THAT REVERSE DRUG RESISTANCE IN DIFFUSE LARGE BCELL LYMPHOMA (DLBCL). 35:253-254. 2017 PETCR AS A SURROGATE FOR SURVIVAL OUTCOMES IN DLBCL: A LITERATURE BASED METAANALYSIS 2019
